Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Exclusive: FDA chief had 'robust discussion' with White House about vaccine timelines

Stock Markets Dec 04, 2020 10:51AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Fauci, Redfield testify at U.S. Senate hearing on coronavirus response in Washington

By Jeff Mason and Julie Steenhuysen

WASHINGTON (Reuters) - The U.S. Food and Drug Administration's chief had a "robust discussion" with the White House this week about the timeline for coronavirus vaccine approvals and believes vaccinating 20 million Americans this year is realistic, he said on Friday.

FDA Commissioner Stephen Hahn declined to lay out a specific timetable for approval of the vaccine developed by Pfizer (NYSE:PFE) and BioNTech but said he hoped the regulator would make a decision this month.

Many federal officials are expecting a vaccine approval within days of a Dec. 10 meeting of experts, though one FDA official recently said an approval decision could take weeks.

"We expect to move quickly," after that meeting, Hahn told Reuters in an interview.

Britain leapt ahead of the United States this week in approving Pfizer's COVID-19 vaccine, intensifying scrutiny on U.S. regulators as they consider whether to grant emergency use in the country that leads the world in coronavirus infections.

Hahn has come under pressure from outgoing President Donald Trump, who is eager to claim credit for a successful vaccine, to speed up the process.

The FDA head discussed the situation at a White House meeting with chief of staff Mark Meadows earlier this week to explain the timing and the "balancing act" required to make sure a vaccine is safe and effective.

"Mr. Meadows asked for a briefing and we gave it, and it went very well," Hahn told Reuters. "We had a very robust discussion, and I know that term sometimes is loaded, robust, but we did."

Though he declined to give a specific timeline for vaccine approval, Hahn gave a nod to its likelihood by endorsing the White House's goal of having 20 million Americans inoculated by the end of the year.

"I think given what we know about supplies, it is realistic," Hahn said of that goal. "It'll very much depend upon ... the vaccination campaign."

Trump, a Republican who lost the Nov. 3 presidential election to Democrat Joe Biden but has declined to concede the race, said last week he deserved credit for the vaccine.

GETTING TO 20 MILLION

Dealing with the virus that has killed more than 276,000 people in the United States as well as the economic fallout from the crisis is one of Biden's top priorities once he takes office on Jan. 20.

Hahn said Biden's team had not been in touch with him but he would be happy to provide information about the vaccine approval process. The cancer specialist said he had not made plans for a new job after the Biden administration takes over.

To get to 20 million people, the FDA would need to approve both Pfizer's vaccine and the shot developed by Moderna (NASDAQ:MRNA) soon so they can go to the states quickly.

Data from late-stage trials of Moderna's vaccine, which uses the same mRNA technology as the Pfizer/BioNTech shot, is due to be reviewed on Dec. 17.

Based on a scenario in which people get two doses, Pfizer plans to provide the United States with enough vaccine for 12.5 million people and Moderna has said it will have enough for 10 million people this year.

Pfizer and Moderna have tested their products as two-shot vaccines given weeks apart, but Hahn said officials at the agency were combing through their data and might consider them as a single-shot if warranted.

"I can't prejudge what our scientists will decide, but we will look at that," Hahn said. A single shot vaccine would be much easier to manage because it would not require millions of Americans to return for a second shot weeks later, a major logistical challenge for public health officials. Trump's Operation Warp Speed program has struck deals with several drugmakers in an effort to help speed up the search for effective treatments to fight the global pandemic.

Of the vaccines being evaluated, only Johnson & Johnson (NYSE:JNJ)'s candidate is being tested as a single-shot vaccine.

A speedy vaccine approval could be a political win for Trump's outgoing administration, which has been pushing for effective treatments to help restore a sense of normality to daily life and a hard-hit U.S. economy.

Hahn said he would be eager to be inoculated as soon as there is an approval. "I will be first in line and I will encourage my family to take this vaccine," he said.

Exclusive: FDA chief had 'robust discussion' with White House about vaccine timelines
 

Related Articles

Germany stocks lower at close of trade; DAX down 0.31%
Germany stocks lower at close of trade; DAX down 0.31% By Investing.com - Jul 04, 2022

Investing.com – Germany stocks were lower after the close on Monday, as losses in the Retail, Construction and Technology sectors led shares lower. At the close in Frankfurt, the...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (2)
Zack Harding
Zack Harding Dec 04, 2020 11:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wait ...”Biden’s team has not been in contact...”. But, but, Hundreds of thousands more are going to die if Trump doesn’t handover the reins tomorrow ...according to Biden....snd the lame duck media. Lol.
Darwin Edwards
Darwin Edwards Dec 04, 2020 9:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good Luck. what an advantage to have .
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email